Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 3:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 264 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: 1st Line NSCLC Clear all
Terminated Phase 3 Interventional

Trial of Paclitaxel/Carboplatin + PF-3512676 vs Paclitaxel/Carboplatin Alone in Patients With Advanced Non-Small Cell Lung Cancer

NCT00254891
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
PF-3512676 + Paclitaxel + Carboplatin, Paclitaxel + Carboplatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
828 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
89
States / cities
Little Rock, Alaska • Hot Springs, Arkansas • Chula Vista, California + 69 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2015 · Synced Sep 3, 2026, 3:22 AM EDT
Withdrawn Phase 2 Interventional

Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer

NCT07353957
View directory record Official record
Conditions
Lung Cancer - Non Small Cell Squamous, Lung Cancer - Non Small Cell Non-Squamous
Interventions
Petosemtamab + Pembrolizumab
Combination Product
Lead sponsor
Merus B.V.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
6
States / cities
St. Petersburg, Florida • Long Island City, New York • Chattanooga, Tennessee + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 3, 2026, 3:22 AM EDT
Recruiting Phase 2 Interventional

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

NCT06463665
View directory record Official record
Conditions
Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Carcinoma, Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent
Interventions
Olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin or cisplatin, Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC, Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab, Docetaxel
Biological · Drug
Lead sponsor
Genelux Corporation
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
15
States / cities
Bullhead City, Arizona • Clermont, Florida • Coral Springs, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 3, 2026, 3:22 AM EDT
Completed Phase 2 Interventional

Randomized Study Of CP-675,206 or Best Supportive Care Immediately After Platinum-Based Therapy For Non-Small Cell Lung Cancer (NSCLC)

NCT00312975
View directory record Official record
Conditions
Carcinoma, Non-small-cell Lung
Interventions
CP-675,206, best supportive care
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
14
States / cities
Bentonville, Arkansas • Fayetteville, Arkansas • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Sep 3, 2026, 3:22 AM EDT
Completed Phase 2 Interventional Results available

Phase II Safety and Tolerability Trial With Nab-Paclitaxel Plus Carboplatin Followed by Nab-Paclitaxel for First Line Treatment of NSCLC Subjects With ECOG PS 2

NCT02289456
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
nab-Paclitaxel, Carboplatin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
8
States / cities
Boynton Beach, Florida • New Orleans, Louisiana • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Sep 3, 2026, 3:22 AM EDT
Completed Phase 3 Interventional

A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation

NCT01887886
View directory record Official record
Conditions
Non-Squamous Non-Small Cell Lung Cancer
Interventions
erlotinib, onartuzumab, placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
15
States / cities
Bakersfield, California • Fullerton, California • Long Beach, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 3, 2026, 3:22 AM EDT
Completed Phase 2 Interventional Results available

Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)

NCT03664024
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Pembrolizumab, Pemetrexed, Carboplatin, Cisplatin
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
3
States / cities
Aurora, Colorado • Baltimore, Maryland • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Sep 3, 2026, 3:22 AM EDT
Completed Phase 3 Interventional Results available

Phase III of RRM1 & ERCC1 Directed Customized Chemotherapy for the Treatment of Patients With NSCLC

NCT00499109
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Docetaxel, Vinorelbine, Carboplatin, Gemcitabine
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
7
States / cities
Lakeland, Florida • Leesburg, Florida • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2014 · Synced Sep 3, 2026, 3:22 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).

NCT03164616
View directory record Official record
Conditions
Non Small Cell Lung Cancer NSCLC
Interventions
Durvalumab, Tremelimumab, Abraxane + carboplatin, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + carboplatin, Pemetrexed + cisplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
16
States / cities
Phoenix, Arizona • Bakersfield, California • Santa Monica, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 3, 2026, 3:22 AM EDT
Terminated Phase 3 Interventional Results available

LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research

NCT02231164
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
docetaxel, placebo, nintedanib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
9
States / cities
Chandler, Arizona • Fayetteville, Arkansas • Highland, California + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Sep 3, 2026, 3:22 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS

NCT06008093
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Durvalumab, Tremelimumab, Pemetrexed, Pembrolizumab, Carboplatin, Cisplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
47
States / cities
Beverly Hills, California • La Jolla, California • Los Alamitos, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 3, 2026, 3:22 AM EDT
Terminated Phase 2 Interventional Results available

Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC

NCT03425331
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Ipilimumab, Nivolumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 3, 2026, 3:22 AM EDT
Completed Phase 2 Interventional Results available

First Line Chemotherapy Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT00308750
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
enzastaurin, pemetrexed, docetaxel, carboplatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Burlington, North Carolina • Chapel Hill, North Carolina • Columbia, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Sep 3, 2026, 3:22 AM EDT
Completed Phase 3 Interventional Results available

A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)

NCT03976362
View directory record Official record
Conditions
Carcinoma, Squamous Cell, Non-small-cell Lung
Interventions
Pembrolizumab, Carboplatin, Paclitaxel, Nab-paclitaxel, Olaparib, Placebo
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
851 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
18
States / cities
Birmingham, Alabama • Burbank, California • Boca Raton, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 3, 2026, 3:22 AM EDT
Active, not recruiting Phase 2 Interventional

Plasma-Adapted First-Line Pembro In NSCLC

NCT04166487
View directory record Official record
Conditions
NSCLC Stage IV, Metastatic Non-Small Cell Lung Cancer
Interventions
Pembrolizumab, PEMETREXED, CARBOPLATIN, PACLITAXEL, InVision
Drug · Diagnostic Test
Lead sponsor
Julia K. Rotow, MD
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
5
States / cities
Boston, Massachusetts • Brighton, Massachusetts • South Weymouth, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 3, 2026, 3:22 AM EDT
Completed Phase 2 Interventional Results available

First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC

NCT00456261
View directory record Official record
Conditions
Lung Cancer
Interventions
Pemetrexed, Gemcitabine, Bevacizumab, Carboplatin
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
70 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
18
States / cities
Anniston, Alabama • Jonesboro, Arkansas • Fort Myers, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Sep 3, 2026, 3:22 AM EDT
Completed Phase 2 Interventional

Satraplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer

NCT00268970
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Satraplatin in combination with Paclitaxel
Drug
Lead sponsor
Agennix
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 29, 2012 · Synced Sep 3, 2026, 3:22 AM EDT
Completed Phase 3 Interventional Results available

A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC

NCT02364999
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Bevacizumab-Pfizer, Bevacizumab-EU, Paclitaxel, Carboplatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
19
States / cities
Daphne, Alabama • Mobile, Alabama • Highland, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Sep 3, 2026, 3:22 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

NCT05445843
View directory record Official record
Conditions
Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
Interventions
JDQ443
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 3, 2026, 3:22 AM EDT
Completed Phase 3 Interventional Results available

Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer

NCT00540514
View directory record Official record
Conditions
Non-Small Cell Lung Carcinoma
Interventions
Albumin-bound paclitaxel, Paclitaxel, Carboplatin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
1,052 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
31
States / cities
Huntsville, Alabama • Hot Springs, Arkansas • Little Rock, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2019 · Synced Sep 3, 2026, 3:22 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Vaccine Therapy in Patients With Stages IIIB/IV Non-Small Cell Lung Cancer Who Have Finished First-Line Chemotherapy

NCT00534209
View directory record Official record
Conditions
Lung Cancer
Interventions
Allogeneic B7.1/HLA-A1, Placebo
Biological · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Hollywood, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 15, 2017 · Synced Sep 3, 2026, 3:22 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of BA3071 in Patients With Solid Tumors

NCT05180799
View directory record Official record
Conditions
NSCLC, Melanoma
Interventions
BA3071, Nivolumab, Pembrolizumab, Pemetrexed (Alimta)
Biological · Drug
Lead sponsor
BioAtla, Inc.
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
9
States / cities
Los Angeles, California • Atlanta, Georgia • Dyer, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2025 · Synced Sep 3, 2026, 3:22 AM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel

NCT02684461
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Pembrolizumab
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
5
States / cities
Chapel Hill, North Carolina • Raleigh, North Carolina • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2022 · Synced Sep 3, 2026, 3:22 AM EDT
Completed Phase 2 Interventional

A Phase II Study of Epothilone Analog BMS-247550 in Patients With Non-Small Cell Lung Cancer Who Have Failed First Line Platinum Based Chemotherapy

NCT00035516
View directory record Official record
Conditions
Carcinoma, Non-small-cell Lung
Interventions
Epothilone
Drug
Lead sponsor
R-Pharm
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
16
States / cities
Birmingham, Alabama • Sacramento, California • Miami Beach, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2016 · Synced Sep 3, 2026, 3:22 AM EDT